Compare EPR & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | AAPG |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 2.9B |
| IPO Year | 1997 | 2025 |
| Metric | EPR | AAPG |
|---|---|---|
| Price | $51.90 | $30.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $57.06 | $48.50 |
| AVG Volume (30 Days) | ★ 601.2K | 5.1K |
| Earning Date | 10-29-2025 | 11-19-2025 |
| Dividend Yield | ★ 6.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $707,150,000.00 | $54,524,554.00 |
| Revenue This Year | $5.11 | N/A |
| Revenue Next Year | $2.70 | $368.64 |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | ★ 3.73 | N/A |
| 52 Week Low | $41.75 | $16.50 |
| 52 Week High | $61.24 | $48.45 |
| Indicator | EPR | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 50.39 |
| Support Level | $51.76 | $30.00 |
| Resistance Level | $52.95 | $33.09 |
| Average True Range (ATR) | 0.91 | 0.83 |
| MACD | 0.17 | 0.14 |
| Stochastic Oscillator | 49.24 | 72.07 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.